TG Therapeutics
TGTX
135 hedge funds and large institutions have $646M invested in TG Therapeutics in 2019 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 45 increasing their positions, 31 reducing their positions, and 16 closing their positions.
341% more call options, than puts
Call options by funds: $35.8M | Put options by funds: $8.12M
138% more capital invested
Capital invested by funds: $272M → $646M (+$374M)
125% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 16
45% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 31
17% more funds holding
Funds holding: 115 → 135 (+20)
7.39% more ownership
Funds ownership: 51.06% → 58.45% (+7.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$41.3M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$22.8M |
| 3 |
Renaissance Technologies
New York
|
+$8.14M |
| 4 |
Alkeon Capital Management
New York
|
+$7.6M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$7.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$33.6M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$7.01M |
| 3 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
-$4.1M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.84M |
| 5 |
BM
Bridger Management
New York
|
-$3.24M |
TGTX Hedge Fund Activity: Q4 2019 in Review
135 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2019, worth a combined $646M — up 138% from $272M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new TGTX positions and 16 closed out — a net gain of 20 holders — while 45 added to existing stakes and 31 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $41.3M. The largest seller was Millennium Management, cutting an estimated $33.6M.
- 135 institutional investors held TG Therapeutics (TGTX) as of Q4 2019, up from 115 in Q3 2019.
- Funds reported $646M of TG Therapeutics stock for Q4 2019, up 138% quarter-over-quarter.
- 36 funds opened new TG Therapeutics positions in Q4 2019 and 16 closed out, a net change of +20 holders.
- The largest TG Therapeutics buyer in Q4 2019 was Great Point Partners, an estimated $41.3M added.
- The largest TG Therapeutics seller in Q4 2019 was Millennium Management, an estimated $33.6M sold.
Based on aggregated 13F filings for Q4 2019.